0.6483
price up icon7.87%   0.0473
after-market Dopo l'orario di chiusura: .65 0.0017 +0.26%
loading
Precedente Chiudi:
$0.601
Aprire:
$0.62
Volume 24 ore:
1.03M
Relative Volume:
2.93
Capitalizzazione di mercato:
$55.59M
Reddito:
$5.12M
Utile/perdita netta:
$-67.00M
Rapporto P/E:
-0.441
EPS:
-1.47
Flusso di cassa netto:
$-38.94M
1 W Prestazione:
+8.05%
1M Prestazione:
+19.90%
6M Prestazione:
-7.73%
1 anno Prestazione:
-91.32%
Intervallo 1D:
Value
$0.5811
$0.659
Intervallo di 1 settimana:
Value
$0.5226
$0.6741
Portata 52W:
Value
$0.3816
$8.98

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name
Nome
Verrica Pharmaceuticals Inc
Name
Telefono
484-453-3300
Name
Indirizzo
10 NORTH HIGH STREET, WEST CHESTER, PA
Name
Dipendente
71
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-11
Name
Ultimi documenti SEC
Name
VRCA's Discussions on Twitter

Confronta VRCA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRCA
Verrica Pharmaceuticals Inc
0.6483 55.59M 5.12M -67.00M -38.94M -1.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-06 Downgrade H.C. Wainwright Buy → Neutral
2024-11-05 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-07-25 Aggiornamento Needham Hold → Buy
2023-03-22 Iniziato Jefferies Buy
2023-02-13 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-05-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-05-14 Iniziato RBC Capital Mkts Outperform
2020-12-24 Reiterato H.C. Wainwright Buy
2020-07-15 Downgrade BofA Securities Buy → Neutral
2020-06-30 Reiterato H.C. Wainwright Buy
2020-06-24 Iniziato Northland Capital Outperform
2020-03-24 Iniziato Needham Buy
2019-02-21 Iniziato H.C. Wainwright Buy
Mostra tutto

Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie

pulisher
Jun 18, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com

Jun 18, 2025
pulisher
Jun 16, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st

Jun 13, 2025
pulisher
Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 10, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% – Here’s Why - Defense World

Jun 10, 2025
pulisher
Jun 05, 2025

Verrica Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 05, 2025
pulisher
May 30, 2025

Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN

May 30, 2025
pulisher
May 28, 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Verrica Pharmaceuticals CEO Reveals Dermatology Pipeline Updates at Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 25, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen - Defense World

May 25, 2025
pulisher
May 25, 2025

Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00 - Defense World

May 25, 2025
pulisher
May 24, 2025

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline - MSN

May 24, 2025
pulisher
May 22, 2025

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN

May 22, 2025
pulisher
May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025
pulisher
May 20, 2025

Verrica Pharmaceuticals’ SWOT analysis: stock faces cash crunch amid YCANTH growth - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN

May 20, 2025
pulisher
May 20, 2025

Verrica reports high response rate in skin cancer study - MSN

May 20, 2025
pulisher
May 19, 2025

Research Analysts Offer Predictions for VRCA Q2 Earnings - Defense World

May 19, 2025
pulisher
May 16, 2025

Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

May 16, 2025
pulisher
May 15, 2025

Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms - MSN

May 15, 2025
pulisher
May 15, 2025

RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA) - The Globe and Mail

May 15, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals (VRCA) Sees Q1 Revenue Growth Driven by YCANTH - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals (VRCA) Receives Hold Rating from Needham - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlig - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Verrica Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Verrica Pharmaceuticals Q1 2025 results show revenue growth By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

Verrica Pharmaceuticals Q1 2025 Earnings: EPS Misses, Revenue Su - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Verrica Pharmaceuticals Q1 2025 results show revenue growth - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue and Adv - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results - The Manila Times

May 13, 2025
pulisher
May 13, 2025

West Pharmaceutical Services to Present at Upcoming Healthcare and Growth Stock Conferences - MyChesCo

May 13, 2025
pulisher
May 12, 2025

Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result - GuruFocus

May 12, 2025
pulisher
May 11, 2025

Verrica Pharmaceuticals (VRCA) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 11, 2025

Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

May 11, 2025
pulisher
May 08, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - MSN

May 08, 2025
pulisher
May 07, 2025

Verrica Pharmaceuticals at The Citizens JMP Life Sciences Conference: Strategic Developments in Dermatology - Investing.com Canada

May 07, 2025

Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Verrica Pharmaceuticals Inc Azioni (VRCA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Hayes Christopher G.
CHIEF LEGAL OFFICER
Aug 26 '24
Sale
2.66
26,183
69,647
115,303
Hayes Christopher G.
CHIEF LEGAL OFFICER
Aug 27 '24
Sale
2.46
9,530
23,444
105,773
Goldenberg Gary
Chief Medical Officer
Aug 26 '24
Sale
2.66
9,888
26,302
97,862
Goldenberg Gary
Chief Medical Officer
Aug 27 '24
Sale
2.46
3,601
8,858
94,261
Bonaccorso Joe
CHIEF COMMERCIAL OFFICER
Aug 26 '24
Sale
2.66
24,709
65,726
82,107
Bonaccorso Joe
CHIEF COMMERCIAL OFFICER
Aug 27 '24
Sale
2.46
8,993
22,123
73,114
Kohler Terry
CHIEF FINANCIAL OFFICER
Aug 26 '24
Sale
2.66
21,820
58,041
52,596
Kohler Terry
CHIEF FINANCIAL OFFICER
Aug 27 '24
Sale
2.46
7,899
19,432
44,697
White Ted
PRESIDENT AND CEO
Aug 26 '24
Sale
2.66
24,979
66,444
224,988
White Ted
PRESIDENT AND CEO
Aug 27 '24
Sale
2.46
9,021
22,192
215,967
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):